Distribution of cyclosporine a in ocular tissues after topical administration of cyclosporine a cationic emulsions to pigmented rabbits

Cornea

Volumn 32, Issue 3, 2013, Pages 345-354

  Daull, Philippe ^a   Lallemand, Frédéric ^a   Philips, Betty ^a   Lambert, Grégory ^a   Buggage, Ronald ^a   Garrigue, Jean Sébastien ^a  

^a Novagali Pharma   (France)

Author keywords

cationic emulsion; cyclosporine A; dry eye disease; ocular drug delivery; pharmacokinetics

Indexed keywords

CYCLOSPORIN A; NANOCARRIER; NOVA 22007; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CATIONIC EMULSION; CHEMICAL COMPOSITION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; EMULSION; EXPERIMENTAL RABBIT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSMOLALITY; PH; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONJUNCTIVA; CORNEA; CYCLOSPORINE; DRUG CARRIERS; EMULSIONS; FEMALE; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; MALE; MASS SPECTROMETRY; PRESERVATIVES, PHARMACEUTICAL; RABBITS; TISSUE DISTRIBUTION;

EID: 84873985749     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31825e83f4     Document Type: Article

References (33)

1. DEWS. 2007 report of the international Dry Eye WorkShop (DEWS). Ocul Surf. 2007;5:65-204.
2. Baudouin C. A new approach for better comprehension of diseases of the ocular surface [in French]. J Fr Ophtalmol. 2007;30:239-246.
3. Tavares Fde P, Fernandes RS, Bernardes TF, et al. Dry eye disease. Semin Ophthalmol. 2010;25:84-93.
4. Kashani S, Mearza AA. Uses and safety profile of ciclosporin in ophthalmology. Expert Opin Drug Saf. 2008;7:79-89.
5. Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye (Lond). 2001;15:39-41.
6. Perry HD, Doshi SJ, Donnenfeld ED, et al. Topical cyclosporin A in the management of therapeutic keratoplasty for mycotic keratitis. Cornea. 2002;21:161-163.
7. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992;89:3686-3690.
8. Noble S, Markham A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs. 1995;50:924-941.
9. Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330-337.
10. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321-338.
11. De Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2008;71:89-95.
12. Utine CA, Stern M, Akpek EK. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm. 2010;18:352-361.
13. Muchtar S, Almog S, Torracca MT, et al. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits. Ophthalmic Res. 1992;24:142-149.
14. Naveh N, Muchtar S, Benita S. Pilocarpine incorporated into a submicron emulsion vehicle causes an unexpectedly prolonged ocular hypotensive effect in rabbits. J Ocul Pharmacol. 1994;10:509-520.
15. Ding S, Tien W, Olejnik O, inventors. Allergan, Inc, assignee. Nonirritating emulsions for sensitive tissues. US Patent 5 474 979. July 25, 1995.
16. Acheampong A, Shackleton M, Lam S, et al. Cyclosporine distribution into the conjunctiva, cornea, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog, and human eyes. Adv Exp Med Biol. 1998;438:1001-1004.
17. Acheampong AA, Shackleton M, Tang-Liu DD, et al. Distribution of cyclosporin A in ocular tissues after topical administration to albino rabbits and beagle dogs. Curr Eye Res. 1999;18:91-103.
18. Aiache JM, el Meski S, Beyssac E, et al. The formulation of drug for ocular administration. J Biomater Appl. 1997;11:329-348.
19. Royle L, Matthews E, Corfield A, et al. Glycan structures of ocular surface mucins in man, rabbit and dog display species differences. Glycoconj J. 2008;25:763-773.
20. Rabinovich-Guilatt L, Couvreur P, Lambert G, et al. Cationic vectors in ocular drug delivery. J Drug Target. 2004;12:623-633.
21. Klang S, Abdulrazik M, Benita S. Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. Pharm Dev Technol. 2000;5:521-532.
22. Chien DS, Homsy JJ, Gluchowski C, et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr Eye Res. 1990;9:1051-1059.
23. Tamilvanan S, Khoury K, Gilhar D, et al. Ocular delivery of cyclosporin A. I. Design and characterization of cyclosporin A-loaded positively-charged submicron emulsion. STP Pharma Sci. 2001;11: 421-426.
24. Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307-318.
25. Tamilvanan S, Benita S. The potential of lipid emulsion for ocular delivery of lipophilic drugs. Eur J Pharm Biopharm. 2004;58:357-368.
26. Philips B, Bague S, Rabinovich-guilatt L, et al, inventors. Novagali Pharma SAS, assignee. Ophthalmic emulsions containing an immunosuppressive agent. EP Patent 1 809 238. October 29, 2008.
27. Bonduelle S, Carrier M, Pimienta C, et al. Tissue concentration of nanoencapsulated radio-labelled cyclosporin following peroral delivery in mice or ophthalmic application in rabbits. Eur J Pharm Biopharm. 1996;42:313-319.
28. Hubert P, Nguyen-Huu JJ, Boulanger B, et al. Validation of quantitative analytical procedure, Harmonization of approaches. STP Pharma Pratiques. 2003;13:101-138.
29. Grass GM, Lee VH. A model to predict aqueous humor and plasma pharmacokinetics of ocularly applied drugs. Invest Ophthalmol Vis Sci. 1993;34:2251-2259.
30. Abdulrazik M, Tamilvanan S, Khoury K, et al. Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A. STP Pharma Sci. 2001;11:427-432.
31. Beilin M, Bar-llan A, Amselem S. Ocular retention time of submicron emulsion (SME) and the miotic response to pilocarpine delivered in SME. Invest Opthalmol Vis Sci. 1995;32:S166.
32. Tang-Liu DD, Acheampong A. Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye. Clin Pharmacokinet. 2005;44:247-261.
33. Barabino S, Montaldo E, Solignani F, et al. Immune response in the conjunctival epithelium of patients with dry eye. Exp Eye Res. 2010;91:524-529.